Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Izenivetmab was authorized for veterinary use in Canada in October 2025, and in the European Union in November 2025.
Medical uses Izenivetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.
Society and culture Legal status Izenivetmab was authorized for veterinary use in Canada in October 2025, and in the European Union in November 2025.
Names Izenivetmab is the international nonproprietary name.
Izenivetmab is sold under the brand name Lenivia.
References
External links